Hologic announced that it has obtained the CE Mark for its Affirm® Contrast Biopsy Software, enabling its commercialization in the European Union. This regulatory approval expands the market reach for Hologic's breast health products.
The Affirm® Contrast Biopsy Software is designed to enhance breast biopsy procedures, offering improved diagnostic capabilities. This development supports Hologic's strategy to provide advanced solutions across the breast health continuum of care.
Securing the CE Mark is an important step for international growth, allowing healthcare providers in the EU to access this technology and potentially improve patient outcomes in breast cancer diagnosis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.